X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter

By Guest Contributor  |    November 7, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

By Katie Koziara  |    November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....   Read More

5 Ways to improve ICER’s value assessment framework

By Lauren Neves  |    June 20, 2019
The Institute for Clinical and Economic Review’s (ICER) recently made a call for suggestions and feedback on how to improve its value assessment framework and methods. We are a strong supporter of...   Read More

Assessing value top of mind at ISPOR 2019

By Samantha Dougherty  |    June 5, 2019
As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how...   Read More

Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care

By Katie Koziara  |    October 2, 2018
Tomorrow, October 3, PhRMA will convene health care leaders for a discussion on how we can move our health care system toward one focused on value rather than volume, ensuring patients can access...   Read More

New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers

By Lauren Neves  |    September 19, 2018
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...   Read More

Guest post: Developing new payment models to ensure patients have access to high-investment therapies

By Guest Contributor  |    September 6, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Number of value-based contracts continues to rise

By Michelle Drozd  |    August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...   Read More

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

By Randy Burkholder  |    July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?   Read More

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

By Holly Campbell  |    July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates